论文信息 - First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide - 字舞流文

First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

W. Kim | K. Reddy | D. Dieterich | P. Kwo | N. Afdhal | M. Tong | M. Curry | S. Milligan | H. Hann | C. Pan | H. Bae | Andrew Frick | Lynn M. Frazier | V. Ankoma‐Sey